• Tuesday, Jun 28, 2022
  • Last Update : 03:54 pm

Peru study finds Sinopharm Covid vaccine 50.4% effective against infections

  • Published at 08:47 am August 14th, 2021
Sinopharm vaccine
File photo of the Covid-19 vaccine made by the Beijing Institute of Biological Products, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), taken on April 15, 2021 Reuters

The vaccine, however, is 94% effective at preventing deaths after two doses, the research shows

A two-dose Covid-19 vaccine from China's Sinopharm was 50.4% effective in preventing infections in health workers in Peru when it was seeing a surge in cases fuelled by virus variants, and booster shots can be considered, a study found.

The study involving Sinopharm's BBIBP-CorV vaccine, which looked at data from February through June at a time when Peru was fighting a brutal second-wave of infections fuelled by the Lambda and Gamma variants of coronavirus, was conducted on nearly 400,000 frontline health workers in live conditions.

Most of the health workers received two doses of the vaccine.

"The efficacy to prevent infection is not high and this is something to consider once a high percentage of the population receives its two doses, (the) moment when boosters can be considered to optimize the protection of frontline health workers," said the study published last week from scientists at Peru's National Institute of Health and two other research institutes.

The vaccine, however, was 94% effective at preventing deaths after two doses, it added.

Some countries including Cambodia and the United Arab Emirates have offered vaccines made by AstraZeneca or Pfizer as boosters to those who received doses developed by China's Sinopharm.


Also Read - Bangladesh to sign MoU on co-production of Sinopharm vaccine on Monday


"The most likely thing is that you will indeed need a third dose at some point, the question is when is the best moment and with what type of vaccine," Lely Solari, one of the seven authors of the paper, told Reuters in an interview.

Solari said that while the efficacy of Sinopharm's vaccine against infections was found to be low, it was still acceptable by the World Health Organization (WHO) standards.

The vaccine had shown a 78.1% efficacy rate against symptomatic Covid-19 cases in Phase III clinical trials, WHO data showed. An announcement from Peru's Ministry of Health said last month the vaccine was 98% effective against deaths.

Peru has the highest pandemic death count per capita in the world, which scientists say was caused by the Lambda variant first identified late last year and made worse by a fragile healthcare system.

The Lambda variant recently grabbed headlines because of its spread in the United States and other Latin American nations, though several infectious disease experts said the spread of the variant may be receding.

The variant is more resistant to antibodies triggered by vaccines than the original version of the virus that emerged from Wuhan based on lab study results, Japanese researchers said in a paper ahead of peer review.

While the Peru study included asymptomatic infections, Solari cautioned that they did not conduct real-time testing to identify infections rigorously.

"The vast majority of tests took place because health workers developed symptoms," Solari said. "Some got tested because they suspected infection, but the vast majority was because they had symptoms."

Peruvian health workers were vaccinated exclusively with the Sinopharm shot because that was the first to arrive in Peru and their group was the first to be vaccinated. The country has also vaccinated some people with vaccines from Pfizer and AstraZeneca.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail